Teva markets Tetridar® (teriparatide). The Patient Information Leaflet and Summary of Product Characteristics can be downloaded from the Health Products Regulatory Authority (HRPA) website. For further information about Teva's medicine(s) you can contact Teva's Medical Information Service by email or telephone: +44 (0) 207 540 7117.
Brand name for teriparatide: Tetridar®
Form: Solution for injection in pre-filled pen
Strength: 20 micrograms per 80 microlitres
Pack size: Tetridar® is available in pack size of 1 pen. Each pen contains 28 doses of 20 micrograms (per 80 microlitres).
Instructions on how to use the Tetridar® (teriparatide) pen:
Please read your patient information leaflet carefully before you start using this medicine because it contains important information for you, including step by step instructions on how to administer Tetridar®. You should not inject yourself until you have been trained by your doctor or nurse. You should also contact them if you have any further questions.
Information on Teva products
For Teva products, our Patient Information Leaflets (PILs) are available to download from the HPRA website https://www.hpra.ie. If you are still having difficulty or have any questions regarding your medication please contact us at tel: +44 207 540 7117 or via email: email@example.com
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the Patient Information Leaflet. You can also report side effects directly via the HRPA website or directly to our Medical Information team by using the contact deails above. By reporting side effects you can help provide more information on the safety of a medicine.
Date of Preparation: July 2020